<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04273269</url>
  </required_header>
  <id_info>
    <org_study_id>P1-GM-101</org_study_id>
    <nct_id>NCT04273269</nct_id>
  </id_info>
  <brief_title>A Safety and Efficacy Study of LYS-GM101 Gene Therapy in Patients With GM1 Gangliosidosis</brief_title>
  <official_title>An Open-Label Adaptive-Design Study of Intracisternal Adenoassociated Viral Vector Serotype rh.10 Carrying the Human β-Galactosidase cDNA for Treatment of GM1 Gangliosidosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LYSOGENE</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LYSOGENE</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      LYS-GM101 is a gene therapy for GM1 gangliosidosis intended to deliver a functional copy of&#xD;
      the GLB1 gene to the central nervous system. This study will assess, in a 2-stage&#xD;
      adaptive-design, the safety and efficacy of treatment in subjects with infantile GM1&#xD;
      gangliosidosis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      GM1 gangliosidosis is a fatal autosomal recessive disease caused by mutations in the GLB1&#xD;
      gene leading to accumulation of GM1 ganglioside in neurons and progressive neurodegeneration.&#xD;
      There are three pediatric subtypes: early infantile, late infantile and juvenile. This is an&#xD;
      interventional, multicenter, single-arm, 2-stage adaptive design study of LYS-GM101. In the&#xD;
      first safety and proof-of-concept stage of the study, 4 subjects with infantile GM1&#xD;
      gangliosidosis will receive a single dose of LYS-GM101 by intracisternal injection. The&#xD;
      second stage of the study is confirmatory and will include additional patients with GM1&#xD;
      gangliosidosis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 11, 2021</start_date>
  <completion_date type="Anticipated">June 2025</completion_date>
  <primary_completion_date type="Anticipated">June 2025</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Stage 1: Physical examination by body system</measure>
    <time_frame>Up to 6 months (multiple visits)</time_frame>
    <description>Physical examination by body system: normal/abnormal and change from previous assessment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Stage 1: Neurological examination</measure>
    <time_frame>Up to 6 months (multiple visits)</time_frame>
    <description>Neurological examination: normal/abnormal motor activity and coordination, and change from previous assessment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Stage 1: Vital signs: change from baseline in heart rate</measure>
    <time_frame>Up to 6 months (multiple visits)</time_frame>
    <description>Vital signs: change from baseline in heart rate</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Stage 1: Vital signs: change from baseline in body temperature</measure>
    <time_frame>Up to 6 months (multiple visits)</time_frame>
    <description>Vital signs: change from baseline in body temperature</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Stage 1: Vital signs: change from baseline in diastolic and systolic blood pressure</measure>
    <time_frame>Up to 6 months (multiple visits)</time_frame>
    <description>Vital signs: change from baseline in diastolic and systolic blood pressure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Stage 1: Imaging: presence of bleeding post-administration</measure>
    <time_frame>Up to 6 months (multiple visits)</time_frame>
    <description>Imaging: presence of bleeding post-administration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Stage 1: Change from baseline in biochemistry laboratory parameters</measure>
    <time_frame>Up to 6 months (multiple visits)</time_frame>
    <description>Change from baseline in biochemistry laboratory parameters</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Stage 1: Change from baseline in coagulation and hematology laboratory parameters</measure>
    <time_frame>Up to 6 months (multiple visits)</time_frame>
    <description>Change from baseline in coagulation and hematology laboratory parameters</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Stage 1: Incidence of treatment-emergent adverse event and serious adverse events</measure>
    <time_frame>Up to 6 months (multiple visits)</time_frame>
    <description>Incidence of treatment-emergent adverse event and serious adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Stage 1: Assessment of humoral immune response by measurement of antibodies anti-AAV and anti-beta-galactosidase (ELISA) and cellular immune response by beta-galactosidase-specific T-cell proliferation assay</measure>
    <time_frame>Up to 6 months (multiple visits)</time_frame>
    <description>Assessment of humoral immune response by measurement of antibodies anti-AAV and anti-beta-galactosidase (ELISA) and cellular immune response by beta-galactosidase-specific T-cell proliferation assay</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Motor Function</measure>
    <time_frame>Up to 2 years (multiple visits)</time_frame>
    <description>Assess change from baseline in motor function using the Hammersmith Infant Neurological Evaluation (HINE) or Hammersmith Functional Motor Scale-Expanded (HFMSE) instruments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brain MRI</measure>
    <time_frame>Up to 2 years (multiple visits)</time_frame>
    <description>Assess brain atrophy and brain volume</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Developmental changes (VABS-II)</measure>
    <time_frame>Up to 2 years (multiple visits)</time_frame>
    <description>Assess developmental change from baseline in the Vineland Adaptive Behavior Scale-II-Expanded Interview (VABS-II) instrument</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Developmental changes (BSID-III or KABC-II)</measure>
    <time_frame>Up to 2 years (multiple visits)</time_frame>
    <description>Assess developmental change from baseline in the Bayley Scales of Infant and Toddler Development, 3rd Edition (BSID-III) or the Kaufman Assessment Battery for Children, 2nd Edition (KABC-II) instruments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood and cerebrospinal fluid (CSF) biomarkers (beta-galactosidase)</measure>
    <time_frame>Up to 2 years (multiple visits)</time_frame>
    <description>Assess change in beta-galactosidase activity measured from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood and cerebrospinal fluid (CSF) biomarkers (GM1 ganglioside)</measure>
    <time_frame>Up to 2 years (multiple visits)</time_frame>
    <description>Assess change in GM1 ganglioside level measured from baseline</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">16</enrollment>
  <condition>GM1 Gangliosidosis</condition>
  <arm_group>
    <arm_group_label>8x10^12 vg/Kg LYS-GM101</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive a single infusion: 8x10^12 vg/Kg LYS-GM101</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>LYS-GM101</intervention_name>
    <description>LYS-GM101 is an adeno-associated viral vector serotype rh.10 (AAVrh.10) carrying the human β-galactosidase gene, formulated as a suspension for injection</description>
    <arm_group_label>8x10^12 vg/Kg LYS-GM101</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Documented GM1 gangliosidosis diagnosis based on genotyping confirming the β-gal gene&#xD;
             mutations and/or documented deficiency of β-gal enzyme by laboratory testing&#xD;
&#xD;
          -  Children with early infantile GM1 gangliosidosis less than 12 months of age with&#xD;
             ability to swallow&#xD;
&#xD;
          -  Children with late infantile GM1 gangliosidosis less than 3 years of age with ability&#xD;
             to sit&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Uncontrolled seizure disorder. Patients who are stable on anti-convulsive medications&#xD;
             may be included&#xD;
&#xD;
          -  More than 40% brain atrophy as measured by MRI total brain volume at screening&#xD;
&#xD;
          -  Current participation in a clinical trial of another investigational medicinal product&#xD;
&#xD;
          -  Past participation in a gene therapy trial&#xD;
&#xD;
          -  History of hematopoietic stem cell transplantation&#xD;
&#xD;
          -  Any condition that would contraindicate treatment with immunosuppressant therapy&#xD;
&#xD;
          -  Presence of concomitant medical condition or anatomical abnormality precluding lumbar&#xD;
             puncture or intracisternal injection&#xD;
&#xD;
          -  Presence of any permanent items (e.g., metal braces) precluding undergoing MRI&#xD;
&#xD;
          -  History of non-GM1 gangliosidosis medical condition that would confound scientific&#xD;
             rigor or interpretation of results&#xD;
&#xD;
          -  Rare and unrelated serious comorbidities, e.g., Down syndrome, intraventricular&#xD;
             hemorrhage in the new-born period, extreme low birth weight (&lt;1500 grams) or known&#xD;
             bleeding disorders&#xD;
&#xD;
          -  Any vaccination 1 month prior to the planned immunosuppressant treatment&#xD;
&#xD;
          -  Serology consistent with HIV exposure or consistent with active hepatitis B or C&#xD;
             infection&#xD;
&#xD;
          -  Grade 2 or higher lab abnormalities for Liver function tests (LFT), bilirubin,&#xD;
             creatinine, hemoglobin, white blood cell (WBC) count, platelet count, prothrombin time&#xD;
             (PT), and partial thromboplastin time (PTT), according to CTCAE v5.0&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>3 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Operations</last_name>
    <role>Study Director</role>
    <affiliation>LYSOGENE</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lysogene Trial Inquiries</last_name>
    <phone>+33 (0)1 41 43 03 90</phone>
    <email>patientadvocacy@lysogene.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Children's Hospital of Orange County (CHOC)</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nina Movsesyan, PhD</last_name>
      <phone>714-509-3008</phone>
      <email>nmovsesyan@choc.org</email>
    </contact>
    <contact_backup>
      <last_name>Ingrid Channa</last_name>
      <phone>909-732-8205</phone>
      <email>Ingrid.Channa@choc.org</email>
    </contact_backup>
    <investigator>
      <last_name>Raymond Wang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Armand-Trousseau, Centre de Référence des Maladies Lysosomales (CRML), Service de Neuropédiatrie</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aurélie Phelep, Ph.D</last_name>
      <email>a.phelep@institut-myologie.org</email>
    </contact>
    <contact_backup>
      <last_name>Rose-Diana Ho</last_name>
      <email>rd.ho@institut-myologie.org</email>
    </contact_backup>
    <investigator>
      <last_name>Bénédicte Héron, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Claudia Ravelli, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Manchester University NHS Foundation Trust</name>
      <address>
        <city>Manchester</city>
        <zip>M13 9WL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Crowther</last_name>
      <email>genetics.research@mft.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Simon Jones, MBChB</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>January 21, 2020</study_first_submitted>
  <study_first_submitted_qc>February 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 18, 2020</study_first_posted>
  <last_update_submitted>June 30, 2021</last_update_submitted>
  <last_update_submitted_qc>June 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>GM1 Gangliosidosis</keyword>
  <keyword>Lysosomal Storage Disease</keyword>
  <keyword>Landing Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gangliosidoses</mesh_term>
    <mesh_term>Gangliosidosis, GM1</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

